Logo-apb
Adv Pharm Bull. 2015;5(5): 605-614. doi: 10.15171/apb.2015.082
PMID: 26793605        PMCID: PMC4708030

Review Article

Toll-Like Receptors in the Pathogenesis of Autoimmune Diseases

Akbar Mohammad Hosseini 1, Jafar Majidi 1 * , Behzad Baradaran 1 * , Mehdi Yousefi 2,1

Cited by CrossRef: 31


1- Zhao L, Fu Z. Roles of Host Immunity in Viral Myocarditis and Dilated Cardiomyopathy. Journal of Immunology Research. 2018;2018:1 [Crossref]
2- Aslaksen S, Wolff A, Vigeland M, Breivik L, Sheng Y, Oftedal B, Artaza H, Skinningsrud B, Undlien D, Selmer K, Husebye E, Bratland E. Identification and characterization of rare toll-like receptor 3 variants in patients with autoimmune Addison's disease. Journal of Translational Autoimmunity. 2019;1:100005 [Crossref]
3- Pearson J, Wong F, Wen L. Crosstalk between circadian rhythms and the microbiota. Immunology. 2020;161(4):278 [Crossref]
4- Li Y, Sun H, Yin Z, Guo X, Yan J. Anti-Inflammatory Effects of Cerium Dioxide Nanoparticles on Peritonitis in Rats Induced by Staphylococcus epidermidis Infection. Advances in Polymer Technology. 2020;2020:1 [Crossref]
5- Mortazavi Jahromi S, Jamshidi M, Yousefi M, Navabi S, Motamed N, Zavareh F, Mirshafiey A. Inhibitory effect of G2013 molecule as a novel immunomodulatory agent, on miR-155 gene expression in HEK-Blue hTLR4 cell line. Eur J Inflamm. 2016;14(2):86 [Crossref]
6- Han J, Tong H, Cheng S, Yang L, Chen H, Chen J, Chen X. Effect of Kangshuanyihao Formula on the Inflammatory Reaction and SIRT1/TLR4/NF-κB Signaling Pathway in Endothelial Injury. Evidence-Based Complementary and Alternative Medicine. 2017;2017:1 [Crossref]
7- Pahlavan Y, Samadi N, Ansarin K, Khabbazi A. Phosphorylation Modulates Survivin Function in Behcet’s Disease. Adv Pharm Bull. 2020;10(2):278 [Crossref]
8- Oakes R, Froimchuk E, Jewell C. Engineering Biomaterials to Direct Innate Immunity. Adv Therap. 2019;2(6):1800157 [Crossref]
9- Taylor E, Wolf V, Dent E, Ryan M. Mechanisms of hypertension in autoimmune rheumatic diseases. Br J Pharmacol. 2019;176(12):1897 [Crossref]
10- Mertowski S, Grywalska E, Ludian J, Grafka A, Pęksa B, Roliński J, Załuska W. The significance of Toll-like receptors in selected nephropathies. diagn lab. 2019;55(2):107 [Crossref]
11- Tröscher A, Wimmer I, Quemada-Garrido L, Köck U, Gessl D, Verberk S, Martin B, Lassmann H, Bien C, Bauer J. Microglial nodules provide the environment for pathogenic T cells in human encephalitis. Acta Neuropathol. 2019;137(4):619 [Crossref]
12- Ziegler S, Feldmann C, Hagen S, Richert L, Barkhausen T, Goletzke J, Jazbutyte V, Martrus G, Salzberger W, Renné T, Hecher K, Diemert A, Arck P, Altfeld M. Innate immune responses to toll-like receptor stimulation are altered during the course of pregnancy. Journal of Reproductive Immunology. 2018;128:30 [Crossref]
13- Guo A, Tan Y, Liu C, Zheng X. MST-4 and TRAF-6 expression in the peripheral blood mononuclear cells of patients with Graves’ disease and its significance. BMC Endocr Disord. 2017;17(1) [Crossref]
14- Imbrechts M, De Samblancx K, Fierens K, Brisse E, Vandenhaute J, Mitera T, Libert C, Smets I, Goris A, Wouters C, Matthys P. IFN-γ stimulates CpG-induced IL-10 production in B cells via p38 and JNK signalling pathways. Eur J Immunol. 2018;48(9):1506 [Crossref]
15- Kızıldağ S, Arslan S, Özbilüm N, Engin A, Bakır M. Effect of TLR10 (2322A/G, 720A/C, and 992T/A) polymorphisms on the pathogenesis of Crimean Congo hemorrhagic fever disease. J Med Virol. 2018;90(1):19 [Crossref]
16- Shakya A, Nandakumar K. Antigen-Specific Tolerization and Targeted Delivery as Therapeutic Strategies for Autoimmune Diseases. Trends in Biotechnology. 2018;36(7):686 [Crossref]
17- Frizinsky S, Haj-Yahia S, Machnes Maayan D, Lifshitz Y, Maoz-Segal R, Offengenden I, Kidon M, Agmon-Levin N. The innate immune perspective of autoimmune and autoinflammatory conditions. 2019;58(Supplement_6):vi1 [Crossref]
18- Huang S, Mei H, Zhang D, Shi T, Chen L, Kuang Z, Heng Y, Pan X, Lu L. Subtle differences in chemical pattern between human toll‐like receptor 8 agonists and antagonists: Emerging chemical patterns analysis. Chem Biol Drug Des. 2019;94(4):1824 [Crossref]
19- Root-Bernstein R. Innate Receptor Activation Patterns Involving TLR and NLR Synergisms in COVID-19, ALI/ARDS and Sepsis Cytokine Storms: A Review and Model Making Novel Predictions and Therapeutic Suggestions. IJMS. 2021;22(4):2108 [Crossref]
20- Golden L, Itoh Y, Itoh N, Iyengar S, Coit P, Salama Y, Arnold A, Sawalha A, Voskuhl R. Parent-of-origin differences in DNA methylation of X chromosome genes in T lymphocytes. Proc Natl Acad Sci USA. 2019;116(52):26779 [Crossref]
21- Dela Justina V, Giachini F, Priviero F, Webb R. Double-stranded RNA and Toll-like receptor activation: a novel mechanism for blood pressure regulation. 2020;134(2):303 [Crossref]
22- Robinet M, Maillard S, Cron M, Berrih-Aknin S, Le Panse R. Review on Toll-Like Receptor Activation in Myasthenia Gravis: Application to the Development of New Experimental Models. Clinic Rev Allerg Immunol. 2017;52(1):133 [Crossref]
23- Hajiasgharzadeh K, Sadigh‐Eteghad S, Mansoori B, Mokhtarzadeh A, Shanehbandi D, Doustvandi M, Asadzadeh Z, Baradaran B. Alpha7 nicotinic acetylcholine receptors in lung inflammation and carcinogenesis: Friends or foes?. J Cell Physiol. 2019;234(9):14666 [Crossref]
24- Roozbehkia M, Mahmoudi M, Aletaha S, Rezaei N, Fattahi M, Jafarnezhad-Ansariha F, Barati A, Mirshafiey A. The potent suppressive effect of β- d -mannuronic acid (M2000) on molecular expression of the TLR/NF-kB Signaling Pathway in ankylosing spondylitis patients. International Immunopharmacology. 2017;52:191 [Crossref]
25- Al-Humairi R, Al-Musawi M, Ad'hiah A. Bidirectional expression of Toll-like receptor 7 gene in urinary bladder cancer and urinary tract infection of Iraqi patients. Gene Reports. 2019;17:100491 [Crossref]
26- Abdelwahab A, Palosaari S, Abdelwahab S, Rifaai R, El-Tahawy N, Saber E, Nousiainen T, Valkealahti M, Huhtakangas J, Karttunen T, Lehenkari P. Differential synovial tissue expression of TLRs in seropositive and seronegative rheumatoid arthritis: A preliminary report. Autoimmunity. 2021;54(1):23 [Crossref]
27- Root-Bernstein R. Synergistic Activation of Toll-Like and NOD Receptors by Complementary Antigens as Facilitators of Autoimmune Disease: Review, Model and Novel Predictions. IJMS. 2020;21(13):4645 [Crossref]
28- Feng J, Lin P, Wang Y, Zhang Z. Molecular characterization, expression patterns, and functional analysis of toll-interacting protein (Tollip) in Japanese eel Anguilla japonica. Fish & Shellfish Immunology. 2019;90:52 [Crossref]
29- Yang X, Cheng Y, Li C. The role of TLRs in cervical cancer with HPV infection: a review. Sig Transduct Target Ther. 2017;2(1) [Crossref]
30- Lee F, Davidson K, Harris C, McClendon J, Janssen W, Alper S. NF-κB mediates lipopolysaccharide-induced alternative pre-mRNA splicing of MyD88 in mouse macrophages. Journal of Biological Chemistry. 2020;295(18):6236 [Crossref]
31- Dvornikova K, Bystrova E, Platonova O, Churilov L. Polymorphism of toll-like receptor genes and autoimmune endocrine diseases. Autoimmunity Reviews. 2020;19(4):102496 [Crossref]
32- Vijay K. Toll-like receptors in immunity and inflammatory diseases: Past, present, and future. International Immunopharmacology. 2018;59:391 [Crossref]
33- Hassan A, Shoeib S, Abdelmohsen E, Nazir A, Dawood A, Gamal H, Abdelhafez M. Toll-Like Receptor 9 (TLR9) Gene C/T (rs352140) Polymorphisms in Adult Primary Immune Thrombocytopenia. Clin Appl Thromb Hemost. 2020;26:107602962094005 [Crossref]
34- Mertowski S, Lipa P, Morawska I, Niedźwiedzka-Rystwej P, Bębnowska D, Hrynkiewicz R, Grywalska E, Roliński J, Załuska W. Toll-Like Receptor as a Potential Biomarker in Renal Diseases. IJMS. 2020;21(18):6712 [Crossref]
35- Mishra V, Pathak C. Human Toll-Like Receptor 4 (hTLR4): Structural and functional dynamics in cancer. International Journal of Biological Macromolecules. 2019;122:425 [Crossref]
36- Griffin J, Song J, Sestak J, DeKosky B, Berkland C. Linking autoantigen properties to mechanisms of immunity. Advanced Drug Delivery Reviews. 2020;165-166:105 [Crossref]
37- Mortazavi-Jahromi S, Jamshidi M, Farazmand A, Aghazadeh Z, Yousefi M, Mirshafiey A. Pharmacological effects of β-d-mannuronic acid (M2000) on miR-146a, IRAK1, TRAF6 and NF-κB gene expression, as target molecules in inflammatory reactions. Pharmacological Reports. 2017;69(3):479 [Crossref]
38- Gershony L, Belanger J, Hytönen M, Lohi H, Famula T, Oberbauer A. Genetic characterization of Addison’s disease in Bearded Collies. BMC Genomics. 2020;21(1) [Crossref]
39- Brutkiewicz R. Cell Signaling Pathways That Regulate Antigen Presentation. JI. 2016;197(8):2971 [Crossref]
40- Zhang S, Hu Z, Tanji H, Jiang S, Das N, Li J, Sakaniwa K, Jin J, Bian Y, Ohto U, Shimizu T, Yin H. Small-molecule inhibition of TLR8 through stabilization of its resting state. Nat Chem Biol. 2018;14(1):58 [Crossref]
41- Merrheim J, Villegas J, Van Wassenhove J, Khansa R, Berrih-Aknin S, le Panse R, Dragin N. Estrogen, estrogen-like molecules and autoimmune diseases. Autoimmunity Reviews. 2020;19(3):102468 [Crossref]
42- Kiziltas S. Toll-like receptors in pathophysiology of liver diseases. WJH. 2016;8(32):1354 [Crossref]
43- Lai R, Gu M, Jiang W, Lin W, Xu P, Liu Z, Huang H, An H, Wang X. Raf Kinase Inhibitor Protein Preferentially Promotes TLR3-Triggered Signaling and Inflammation. JI. 2017;198(10):4086 [Crossref]
44- Mortazavi-Jahromi S, Farazmand A, Motamed N, Navabi S, Mirshafiey A. Effects of guluronic acid (G2013) on SHIP1, SOCS1 induction and related molecules in TLR4 signaling pathway. International Immunopharmacology. 2018;55:323 [Crossref]
45- Tilstra J, John S, Gordon R, Leibler C, Kashgarian M, Bastacky S, Nickerson K, Shlomchik M. B cell–intrinsic TLR9 expression is protective in murine lupus. 2020;130(6):3172 [Crossref]
46- Buechler C, Pohl R, Aslanidis C. Pro-Resolving Molecules—New Approaches to Treat Sepsis?. IJMS. 2017;18(3):476 [Crossref]
47- Tesovnik T, Kovač J, Pohar K, Hudoklin S, Dovč K, Bratina N, Trebušak Podkrajšek K, Debeljak M, Veranič P, Bosi E, Piemonti L, Ihan A, Battelino T. Extracellular Vesicles Derived Human-miRNAs Modulate the Immune System in Type 1 Diabetes. Front Cell Dev Biol. 2020;8 [Crossref]
48- Bruno K, Woller S, Miller Y, Yaksh T, Wallace M, Beaton G, Chakravarthy K. Targeting toll-like receptor-4 (TLR4)—an emerging therapeutic target for persistent pain states. Pain. 2018;159(10):1908 [Crossref]
49- Zhang Y, Liu J, Wang C, Liu J, Lu W. Toll-Like Receptors Gene Polymorphisms in Autoimmune Disease. Front Immunol. 2021;12 [Crossref]
50- Davies R, Sarkar I, Hammenfors D, Bergum B, Vogelsang P, Solberg S, Gavasso S, Brun J, Jonsson R, Appel S. Single Cell Based Phosphorylation Profiling Identifies Alterations in Toll-Like Receptor 7 and 9 Signaling in Patients With Primary Sjögren's Syndrome. Front Immunol. 2019;10 [Crossref]
51- Wu C, Deng H, Li D, Fan L, Yao D, Zhi X, Mao H, Hu C. Ctenopharyngodon idella Tollip regulates MyD88-induced NF-κB activation. Developmental & Comparative Immunology. 2021;123:104162 [Crossref]